Announcement PDF Form 605 Corporations Act 2001 Section 671B Notice of ceasing to be a substantial holder To Company Name Race Oncology Limited ABN 61 149 318 749 1. Details of substantial holder (1) Name Merchant Funds Management Pty Ltd (ACN 154 493 277) (Merchant) as manager of the Merchant Opportunities Fund (ARSN 111 456 387) and manager of the Merchant Biotech Fund (ARSN 654 495 468) & Merchant Group Pty Ltd (ABN 56 154 832 237). ACN/ARSN (if applicable) See above The holder ceased to be a substantial holder on 21/12/2021 The previous notice was given to the company on 09/03/2021 The previous notice was dated 09/03/2021 2. Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change Person whose relevant interest changed Nature of change (4) Consideration given in relation to change (5) Class (6) and number of securities affected Person’s voted affected Dilution due to SPP share issue - - - Merchant Opportunities Fund 21/12/2021 Merchant Biotech Fund Merchant Group Pty Ltd (Nominee A/C) 11/03/2021 21/12/2021 Merchant Opportunities Fund On/Off Market Trades & SPP -$8,009,173.26 -2,209,532 -2,209,532 15/04/2021 21/12/2021 Merchant Group Pty Ltd (Nominee A/C) On/Off Market Trades, Internal Transfer of Accounts & SPP $1,928,748 524,800 524,800 16/12/2021 21/12/2021 Merchant Biotech Fund On/Off Market Trades $993,820.44 300,000 300,000 3. Changes in association The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable) Nature of association 4. Addresses The addresses of persons named in this form are as follows: Name Merchant Funds Management Pty Ltd Merchant Opportunities Fund Merchant Biotech Fund Merchant Group Pty Ltd Address Level 1, 3 Ord Street, West Perth WA 6005 Level 1, 3 Ord Street, West Perth WA 6005 Level 1, 3 Ord Street, West Perth WA 6005 Level 1, 3 Ord Street, West Perth WA 6005 Signature print name: Andrew Chapman Capacity: Managing Director sign here date 24/12/2021 DIRECTIONS (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form. (2) See the definition of “relevant interest” in sections 608 and 671B(7) of the Corporations Act 2001. (3) See the definition of “associate” in section 9 of the Corporations Act 2001. (4) Include details of: (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies). See the definition of “relevant agreement” in section 9 of the Corporations Act 2001. (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired. (6) The voting shares of a company constitute one class unless divided into separate classes. (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice